tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2022 Aug 4.
doi: 10.1080/14760584.2022.2110075. Online ahead of print.
Vaccines against SARS-CoV-2 variants and future pandemics
Taeyoung Park[SUP] 1 [/SUP], Hyogyeong Hwang[SUP] 1 [/SUP], Suhyeong Moon[SUP] 1 [/SUP], Sang Gu Kang[SUP] 1 [/SUP], Seunghyup Song[SUP] 1 [/SUP], Young Hun Kim[SUP] 1 [/SUP], Hanbi Kim[SUP] 1 [/SUP], Eun-Ju Ko[SUP] 2 [/SUP], Soon-Do Yoon[SUP] 3 [/SUP], Sang-Moo Kang[SUP] 4 [/SUP], Hye Suk Hwang[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Vaccination continues to be the most effective method for controlling COVID-19 infectious diseases. Nonetheless, SARS-CoV-2 variants continue to evolve and emerge, resulting in significant public concerns worldwide even after more than two years since the COVID-19 pandemic. It is significant to better understand how different COVID-19 vaccine platforms work, why SARS-CoV-2 variants continue to emerge, and what options for improving COVID-19 vaccines can be considered to fight against SARS-CoV-2 variants and future pandemics.
Area covered: Here, we reviewed the innate immune sensors in the recognition of SARS-CoV-2 virus, innate and adaptive immunity including neutralizing antibodies by different COVID-19 vaccines. Efficacy comparison of the several COVID-19 vaccine platforms approved to use in humans, concerns about SARS-CoV-2 variants and breakthrough infections, and the options for developing future COIVD-19 vaccines were also covered.
Expert opinion: Owing to the continuous emergence of novel pathogens and the re-emergence of variants, safer and more effective new vaccines are needed. This review is also aimed to provide the knowledge basis for the development of next-generation COVID-19 and pan-coronavirus vaccines to provide cross-protection against new SARS-CoV-2 variants and future coronavirus pandemics.
Keywords: SARS-CoV-2: ACE-2; TMPRSS-2; nucleic acid-based vaccine; universal vaccine.
. 2022 Aug 4.
doi: 10.1080/14760584.2022.2110075. Online ahead of print.
Vaccines against SARS-CoV-2 variants and future pandemics
Taeyoung Park[SUP] 1 [/SUP], Hyogyeong Hwang[SUP] 1 [/SUP], Suhyeong Moon[SUP] 1 [/SUP], Sang Gu Kang[SUP] 1 [/SUP], Seunghyup Song[SUP] 1 [/SUP], Young Hun Kim[SUP] 1 [/SUP], Hanbi Kim[SUP] 1 [/SUP], Eun-Ju Ko[SUP] 2 [/SUP], Soon-Do Yoon[SUP] 3 [/SUP], Sang-Moo Kang[SUP] 4 [/SUP], Hye Suk Hwang[SUP] 1 [/SUP]
Affiliations
- PMID: 35924678
- DOI: 10.1080/14760584.2022.2110075
Abstract
Introduction: Vaccination continues to be the most effective method for controlling COVID-19 infectious diseases. Nonetheless, SARS-CoV-2 variants continue to evolve and emerge, resulting in significant public concerns worldwide even after more than two years since the COVID-19 pandemic. It is significant to better understand how different COVID-19 vaccine platforms work, why SARS-CoV-2 variants continue to emerge, and what options for improving COVID-19 vaccines can be considered to fight against SARS-CoV-2 variants and future pandemics.
Area covered: Here, we reviewed the innate immune sensors in the recognition of SARS-CoV-2 virus, innate and adaptive immunity including neutralizing antibodies by different COVID-19 vaccines. Efficacy comparison of the several COVID-19 vaccine platforms approved to use in humans, concerns about SARS-CoV-2 variants and breakthrough infections, and the options for developing future COIVD-19 vaccines were also covered.
Expert opinion: Owing to the continuous emergence of novel pathogens and the re-emergence of variants, safer and more effective new vaccines are needed. This review is also aimed to provide the knowledge basis for the development of next-generation COVID-19 and pan-coronavirus vaccines to provide cross-protection against new SARS-CoV-2 variants and future coronavirus pandemics.
Keywords: SARS-CoV-2: ACE-2; TMPRSS-2; nucleic acid-based vaccine; universal vaccine.